Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) EBITDA Margin (2020 - 2024)

Historic EBITDA Margin for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to 65.61%.

  • Fulcrum Therapeutics' EBITDA Margin rose 31669800.0% to 65.61% in Q2 2024 from the same period last year, while for Dec 2024 it was 18.89%, marking a year-over-year increase of 39263500.0%. This contributed to the annual value of 11.82% for FY2024, which is 34346600.0% up from last year.
  • According to the latest figures from Q2 2024, Fulcrum Therapeutics' EBITDA Margin is 65.61%, which was up 31669800.0% from 3213.78% recorded in Q4 2023.
  • Fulcrum Therapeutics' EBITDA Margin's 5-year high stood at 65.61% during Q2 2024, with a 5-year trough of 9471.19% in Q1 2023.
  • For the 5-year period, Fulcrum Therapeutics' EBITDA Margin averaged around 2041.4%, with its median value being 1028.79% (2020).
  • Per our database at Business Quant, Fulcrum Therapeutics' EBITDA Margin plummeted by -84441400bps in 2023 and then skyrocketed by 31669800bps in 2024.
  • Fulcrum Therapeutics' EBITDA Margin (Quarter) stood at 420.19% in 2020, then decreased by -12bps to 470.42% in 2021, then crashed by -768bps to 4083.65% in 2022, then rose by 21bps to 3213.78% in 2023, then soared by 102bps to 65.61% in 2024.
  • Its EBITDA Margin was 65.61% in Q2 2024, compared to 3213.78% in Q4 2023 and 3615.28% in Q3 2023.